Peginterferon alfa-2b in the treatment of Chinese patients with HBeAg-positive chronic hepatitis B: A randomized trial

Highlights • A randomized study of patients with HBeAg-positive chronic hepatitis B. • PEG-IFN alfa-2b (1.5 μg/kg/wk or 1.0 μg/kg/wk) was administered for 24 or 48 weeks. • HBeAg loss was greater in patients receiving PEG-IFN (1.5 μg/kg/wk) for 48 weeks. • Secondary measures of efficacy also favor t...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical virology 2014-12, Vol.61 (4), p.509-516
Hauptverfasser:	Cheng, Jun, Wang, Yuming, Hou, Jinlin, Luo, Duande, Xie, Qing, Ning, Qin, Ren, Hong, Ding, Huiguo, Sheng, Jifang, Wei, Lai, Chen, Shijun, Fan, Xiaoling, Huang, Wenxiang, Pan, Chen, Gao, Zhiliang, Zhang, Jiming, Zhou, Boping, Chen, Guofeng, Wan, Mobin, Tang, Hong, Wang, Guiqiang, Yang, Yuxiu, Mohamed, Rosmawati, Guan, Richard, Lee, Tzong-Hsi, Chang, Wen-Hsiung, Zhenfei, Huang, Ye, Zhang, Xu, Daozhen
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Alanine Transaminase - blood Allergy and Immunology Antiviral Agents - adverse effects Antiviral Agents - therapeutic use Asian Continental Ancestry Group DNA, Viral - blood Female Hepatitis B Hepatitis B e Antigens - blood Hepatitis B virus Hepatitis B, Chronic - drug therapy Humans Infectious Disease Interferon-alpha - adverse effects Interferon-alpha - therapeutic use Male Middle Aged Peginterferon Polyethylene Glycols - adverse effects Polyethylene Glycols - therapeutic use Randomized Recombinant Proteins - adverse effects Recombinant Proteins - therapeutic use Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • A randomized study of patients with HBeAg-positive chronic hepatitis B. • PEG-IFN alfa-2b (1.5 μg/kg/wk or 1.0 μg/kg/wk) was administered for 24 or 48 weeks. • HBeAg loss was greater in patients receiving PEG-IFN (1.5 μg/kg/wk) for 48 weeks. • Secondary measures of efficacy also favor the 48-week regimen. • Safety was generally similar with 24- and 48-week regimens.
ISSN:	1386-6532 1873-5967
DOI:	10.1016/j.jcv.2014.08.008